dc.contributor.author
Cantó, Elisabet
dc.contributor.author
Garcia Planella, Esther
dc.contributor.author
Zamora-Atenza, Carlos
dc.contributor.author
Nieto, Juan Camilo
dc.contributor.author
Gordillo, Jordi
dc.contributor.author
Ortiz, Ma. Àngels
dc.contributor.author
Metón Teijeiro, Isidoro
dc.contributor.author
Serrano, Elena
dc.contributor.author
Vegas Lozano, Esteban
dc.contributor.author
García Bosch, Orlando
dc.contributor.author
Juárez Rubio, Cándido
dc.contributor.author
Vidal i Alcorisa, Sílvia
dc.date.issued
2014-07-16T09:02:16Z
dc.date.issued
2014-07-16T09:02:16Z
dc.date.issued
2014-04-09
dc.date.issued
2014-07-16T09:02:18Z
dc.identifier
https://hdl.handle.net/2445/55853
dc.description.abstract
The exact function of interleukin-19 (IL-19) on immune response is poorly understood. In mice, IL-19 up-regulates TNFalpha and IL-6 expression and its deficiency increases susceptibility to DSS-induced colitis. In humans, IL-19 favors a Th2 response and is elevated in several diseases. We here investigate the expression and effects of IL-19 on cells from active Crohn"s disease (CD) patient. Twenty-three active CD patients and 20 healthy controls (HC) were included. mRNA and protein IL-19 levels were analyzed in monocytes. IL-19 effects were determined in vitro on the T cell phenotype and in the production of cytokines by immune cells. We observed that unstimulated and TLR-activated monocytes expressed significantly lower IL-19 mRNA in active CD patients than in HC (logFC =21.97 unstimulated; 21.88 with Pam3CSK4; and 21.91 with FSL-1; p<0.001). These results were confirmed at protein level. Exogenous IL-19 had an anti-inflammatory effect on HC but not on CD patients. IL-19 decreased TNFalpha production in PBMC (850.7675.29 pg/ml vs 2626.06350 pg/ml; p<0.01) and increased CTLA4 expression (22.0461.55% vs 13.9862.05%; p<0.05) and IL-4 production (32.568.9 pg/ml vs 13.562.9 pg/ml; p<0.05) in T cells from HC. IL-10 regulated IL-19 production in both active CD patients and HC. We observed that three of the miRNAs that can modulate IL-19 mRNA expression, were up-regulated in monocytes from active CD patients. These results suggested that IL-19 had an anti-inflammatory role in this study. Defects in IL-19 expression and the lack of response to this cytokine could contribute to inflammatory mechanisms in active CD patients.
dc.format
application/pdf
dc.format
application/pdf
dc.publisher
Public Library of Science (PLoS)
dc.relation
Reproducció del document publicat a: http://doi.org/10.1371/journal.pone.0093910
dc.relation
PLoS One, 2014, vol. 9, num. 4, p. e93910
dc.relation
http://dx.doi.org/10.1371/journal.pone.0093910
dc.rights
cc-by (c) Cantó, Elisabet et al., 2014
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Bioquímica i Biomedicina Molecular)
dc.subject
Citometria de fluxe
dc.subject
Malaltia de Crohn
dc.subject
Resposta immunitària
dc.subject
Flow cytometry
dc.subject
Crohn's disease
dc.subject
Immune response
dc.title
Interleukin-19 impairment in active Crohn's disease patients
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion